Comparative evaluation of voglibose versus pioglitazone on glycaemic control and lipid profile in patients of type 2 diabetes mellitus on glimepiride and metformin in punjabi population

Abstract

Background: Type 2 Diabetes mellitus (DM) is a heterogeneous group of disorders associated with both microvascular and macrovascular complications. Due to progressive nature of type 2 DM, dual / triple drug therapy produce additive effects, less side effects and allows the use of submaximal doses of individual agents. Therefore, the present study was designed to study the effect of voglibose in comparison to pioglitazone on glycaemic and lipid profile as an add-on drug in patients with DM whose glycaemic status was uncontrolled with glimepiride and metformin. Methods: The present study was open, randomized parallel group comparison of two active treatment groups over a six months period. Sixty patients of either sex in the age group of 30-75 years, suffering from type 2 DM, with FBG> 126 mg/dl and HbA1c between 7- 10 % were selected at random. The effect of voglibose and pioglitazone were observed on various parameters i.e. FBG, PPBG, HbA1c and lipid profile (Total cholesterol, TG, LDL, VLDL). Results: At the end of 6 months it was observed that though both pioglitazone and voglibose reduced FBG, PPBG and HbA1C significantly but pioglitazone caused a significantly greater percentage change in FBG as well as in PPBG whereas the difference in mean percentage change in HbA1C was not significant. Also, fall in total cholesterol, TG, LDL and VLDL was significantly greater with pioglitazone than voglibose. Few side effects were observed with voglibose and not with pioglitazone. Conclusions: Though pioglitazone and voglibose were equally effective in lowering HbA1C levels yet pioglitazone showed better results in improving FBG, PPBG and lipid profile as compared to voglibose. Pioglitazone had minimal side effects as compared to voglibose. [Int J Basic Clin Pharmacol 2012; 1(3.000): 160-167

Effectiveness of Second-Line Agents in the Treatment of Uncomplicated Type 2 Diabetes Mellitus: An Observational Tertiary-Care Based Study

“…27 The present study observed a mean decline of 1.19±0. 27 30 In present voglibose treatment group a mean reduction of 83.98 and 118.75 mg/dL in PPBG at 3 and 6 months respectively which was statistically significant.…”

Effectiveness Treatment for Diabetes Prevention: 6-Months Results from the Prediabetes

“…Similarly, study conducted by Amita Jindal et al supports with our study. [25] Moreover, FDC of Metformin with Pioglitazone and FDC of Metformin with Voglibose have an impact on serum Adiponectin and Serum Ghrelin Level and these were increased significantly from baseline to after 6 months. Several previous cross-sectional and longitudinal studies have established that low Adiponectin and Ghrelin levels are associated with increased risk of T2DM.…”

Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report

“…Glycaemic control : There were 26 studies (13 randomized and 13 non-randomized, controlled, comparative CTs) with primary objective to determine efficacy of pioglitazone in T2DM patients. Eight were monotherapy 43 44 45 46 47 48 49 50 , one add-on to metformin 51 , four add-on to sulfonylurea 52 53 54 55 , and eight were add-on to sulphonylurea and metformin combination 56 57 58 59 60 61 62 63 . Two studies evaluated add-on to metformin, sulphonylurea and insulin 64 65 ; three evaluated and noted decrease in α-amylase, glucokinase and gamma-glutamyl transferase activities 66 67 68 .…”